Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Portfolio Pulse from Vandana Singh
Hims & Hers Health expects continued demand for its compounded weight loss products despite resolved supply shortages of Eli Lilly's tirzepatide. The FDA has reminded compounders of legal restrictions, and Novo Nordisk's semaglutide remains in shortage. Hims & Hers Health's Q3 2024 revenue is projected to exceed guidance, with a Hold rating and $23 price target from Truist.
October 04, 2024 | 6:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly's tirzepatide shortage has been resolved, which may stabilize supply and potentially impact pricing and market dynamics for GLP-1 medications.
The resolution of the tirzepatide shortage is significant for Eli Lilly as it stabilizes the supply of their GLP-1 medication. However, the impact on stock price is neutral in the short term as the market may have already priced in this resolution.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Novo Nordisk's semaglutide remains in shortage, which could affect market share and pricing dynamics for GLP-1 medications.
The ongoing shortage of Novo Nordisk's semaglutide may affect their market share and pricing for GLP-1 medications. However, the short-term impact on stock price is neutral as the shortage has been ongoing and may already be reflected in the stock price.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Hims & Hers Health expects strong demand for its compounded weight loss products despite resolved shortages of Eli Lilly's tirzepatide. The company's Q3 2024 revenue is projected to exceed guidance, with a Hold rating and $23 price target from Truist.
Hims & Hers Health is directly impacted by the news as it relates to their compounded weight loss products. Despite the resolution of tirzepatide shortages, demand is expected to remain strong, which is positive for their revenue outlook. The company's Q3 2024 revenue is projected to exceed guidance, and Truist maintains a Hold rating with a $23 price target, indicating a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100